Professional Documents
Culture Documents
Referat Acne Rosacea Februari 2022
Referat Acne Rosacea Februari 2022
FACULTY OF MEDICINE
UNIVERSITAS HASANUDDIN
ACNE ROSACEA
Wahyudi C011171381
Rifah Hijriyani Fahmi C011171578
Angie Ramadhani Koedoeboen C011171801
Shawnee Priscilla Sie XC061201128
Supervisor:
Resident:
dr. Idrianti Idrus, Sp.KK,
dr. Nahda Yaumil C. Haq
M.Kes
DEFINITION
Kang S, Amagai M, Bruckner AL, et.al. Fitzpatrick’s Dermatology. 9th Ed. United States: McGraw-Hill Education; 2019.
EPIDEMIOLOGY
Columbia (3%)
ETIOLOGY
Infectio
Food Drugs
n
Immunologic
al
Other factors:
Vitamin deficiency
Weather Hormonal imbalance
PATHOGENESIS
Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 4th Ed. United States of America: Elsevier Limited;
CLINICAL MANIFESTATIONS
Johnson SM, Berg A, Barr C. Managing Rosacea in the Clinic: From Pathophysiology to Treatment – A Review of the Literature. Journal of Clinical and Aesthetic Dermatology. 2020;13 (4 Suppl
Flushing – pathophysiological neurovascular process in the
central face for >5-10 minutes
Griffiths CEM, Barker J, Bleiker T, Chalmers R, Creamer D. Rook’s Textbook of Dermatology. 9th Ed. West Sussex: John Wiley & Sons, Ltd; 2016.
Kang S, Amagai M, Bruckner AL, et.al. Fitzpatrick’s Dermatology. 9th Ed. United States: McGraw-Hill Education; 2019.
Phymata – a persistent, firm, nonpainful, nonpitting
swelling of the tissue of the nose, chin, forehead, or eyelids.
Rosacea Fulminans
Rosacea Conglobate
Griffiths CEM, Barker J, Bleiker T, Chalmers R, Creamer D. Rook’s Textbook of Dermatology. 9th Ed. West Sussex: John Wiley & Sons, Ltd; 2016.
James, WD, Berger TG, Elston DM. Andrew’s Diseases of the Skin Clinical Dermatology. 11th Ed. United States of America: Elsevier Inc.; 2011.
Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 4th Ed. United States of America: Elsevier Limited; 2018.
DIAGNOSIS
Kang S, Amagai M, Bruckner AL, et.al. Fitzpatrick’s Dermatology. 9th Ed. United States: McGraw-Hill Education; 2019.
DIFFERENTIAL DIAGNOSIS
Kang S, Amagai M, Bruckner AL, et.al. Fitzpatrick’s Dermatology. 9th Ed. United States: McGraw-Hill Education;
2019.
Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 4th Ed. United States of America: Elsevier Limited; 2018.
Perioral Dermatitis
Kang S, Amagai M, Bruckner AL, et.al. Fitzpatrick’s Dermatology. 9th Ed. United States: McGraw-Hill Education;
2019.
Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 4th Ed. United States of America: Elsevier Limited; 2018.
TREATMENT
• A characteristic of rosacea is the sensitivity of the skin on the face with vascular hyperactivity.
• Many patients complain of sensitivity to cleaning materials and cosmetics.
• The patients need to be educated about trigger factors and ways to care for the skin in general as a step
to maintain skin integrity in the long term and for successful treatment.
Topical Therapy
• Tetracycline, Clindamycin, Erythromycin ointment 0,5-2,0%
• Metronidazole 0.75% gel or cream effective for papules and pustules
• Imidazole itself or with ketoconazole or Sulphur 2-5%
• Isotetrinoin cream 0,2%
• Anti-parasite to kill D. folliculorum, for example: Lindane, Crotamiton, benzyl benzoate.
• Low potency corticosteroids (Hydrocortisone 2%)
Systemic Therapy
Medicinal
Patient Physical
Symptoms Maintenance
Management Approved Off Label Interventions
• IPL
Telangiectasia
• Laser
Kang S, Amagai M, Bruckner AL, et.al. Fitzpatrick’s Dermatology. 9th Ed. United States: McGraw-Hill Education; 2019.
Medicinal
Patient Physical
Symptoms Maintenance
Management Approved Off Label Interventions
Kang S, Amagai M, Bruckner AL, et.al. Fitzpatrick’s Dermatology. 9th Ed. United States: McGraw-Hill Education; 2019.
Medicinal
Physical
Symptoms Patient Management Maintenance
Approved Off Label Interventions
Systemic therapy:
• Doxycycline: low-dose
(40 mg) or conventional
dose
• Eyelid hygiene • Low-dose isotretinoin
Ocular Rosacea • Artificial, lipid-
containing tears Topical therapy:
• Cyclosporin A
• Azithromycin
• Tetracycline
• Steroids
Kang S, Amagai M, Bruckner AL, et.al. Fitzpatrick’s Dermatology. 9th Ed. United States: McGraw-Hill Education; 2019.
Non-pharmacologic Therapy
• Rosacea has varying clinical symptoms, ranging from persistent facial redness, flushing, telangiectasia,
papules or pustule, hypertrophy, and ocular symptoms.
• A 2016 Korean study assessed the prognosis of 234 rosacea patients: 120 mixed types, 75 ETR types,
and 39 PPR types. 14 prognosis was assessed after 2 to 72 months. Total remission was obtained at
20.9% (total 49 patients, 23 mixed subtype patients, 8 types of ETR, and 18 types of PPR) with an
average time of 56 months.
CONCLUSION
• Rosacea is a chronic inflammatory skin disease that mainly attacks the cheeks, nose, chin, and forehead.
• Rosacea is characterized by recurrent episodes of flushing or temporary erythema, persistent erythema, phymatous
changes, papules, pustules, and telangiectasia. The eyes may also be involved.
• Because rosacea affects the face, the disease has a profound negative impact on quality of life, self-esteem, and well-
being.
• Topical treatments form the foundation of rosacea therapy and can be highly efficacious in reducing lesions and
decreasing the intensity of erythema. It may also help manage secondary rosacea symptoms. In addition, general
measures, such as avoiding triggers and patient education on proper skin care, work together with rosacea
medications to enhance outcomes.
THANK YOU